Cambrex unveiled plans to expand its manufacturing center of excellence in High Point, NC. The $30 million investment is designed to meet the continually growing demand for small molecule development and manufacturing services.
 
The expansion will add new chemistry laboratories, two new clinical manufacturing suites and include a small-scale commercial manufacturing operation with three work centers and 2,000-liter reactors.
 
This investment will provide Cambrex with the capabilities to handle the latest R&D process research tools and techniques, increase Cambrex’s equipment offerings to support customer’s speed to market goals, and provide a dedicated facility for Orphan Drugs and niche therapies (annual volumes <500kg).
 
Alongside the new infrastructure which focuses on energy savings and efficiency, 78 new jobs will be created in the area. New positions include operations, scientists, quality assurance and administrative personnel.
 
“Cambrex’s mission is to support our pharmaceutical customers in the development and manufacturing of new therapies that improve human health,” said Thomas Loewald, CEO, Cambrex. “As a result of our High Point team’s commitment to providing our customers best-in-class technical expertise, innovative chemistry, and engineering solutions, the facility has seen rapid growth in demand for our development and manufacturing services. We are extremely excited about this expansion in North Carolina, which would not have been possible without the support of the state’s leadership and economic development programs, and their focus on nurturing the region’s skilled and diverse workforce.”
 
A performance-based grant of $200,000 from the One North Carolina Fund will help with Cambrex’s expansion. The One North Carolina Fund provides financial assistance to local governments to help attract economic investment and to create jobs.